Carprotab

Quick links to important sections

Carprotab

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carprotab

Quick Facts

Property Description
Active ingredient Carprofen
Form Tablet (often flavored), Injectable Solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General use Reduction of pain, inflammation, and fever
Origin Synthetic, Propionic Acid Derivative

What Type of Medicine is Carprotab?

Carprotab is a specialized medication containing the single active substance Carprofen, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This high-level pharmacological designation confirms the drug's primary role is to manage pain, reduce swelling, and decrease fever by targeting the chemical processes responsible for inflammation.

Carprofen is chemically defined as an NSAID of the propionic acid class, a category that includes other common substances. Pharmacological studies have clinically recognized Carprofen for its ability to provide reliable analgesic action by altering chemical signaling in the body's pain pathways. This distinction means the drug is effective at managing discomfort by modifying the body's response at the site of inflammation, a key benefit in long-term management scenarios.

Composition, Origin, and Available Forms

The active ingredient, Carprofen, is a synthetic organic compound, chemically classified as a substituted carbazole derivative. The compound is produced via chemical synthesis, not naturally derived. As a differentiating factor, Carprotab is specifically authorized as a veterinary medicinal product, with oral forms often featuring a flavor to aid administration, distinguishing its market positioning from human formulations of NSAIDs.

Carprotab is formulated into common pharmaceutical preparations, primarily as a solid oral form, such as the tablet—which may be scored or chewable—and as an injectable solution. These forms utilize a solid oral matrix or a sterile liquid vehicle, respectively, to deliver the single active substance for either oral or subcutaneous use.

General Purpose and Mechanism Principles

The core benefit of Carprotab is the delivery of a combined anti-inflammatory, analgesic, and antipyretic action to the system. It achieves this by modulating the production of prostaglandins, which are hormone-like substances released at the site of injury or irritation that are responsible for signaling pain and promoting swelling. By limiting the synthesis of these mediators, the drug achieves its general purpose: helping to manage discomfort, reduce swelling, and decrease fevers, thereby assisting in the recovery of physical comfort.

Regulatory References

  1. Carprofen Animal Drug @ FDA

What side effects are possible with Carprotab?

Possible Side Effects and Safety Information

Carprotab is a non-steroidal anti-inflammatory drug (NSAID) and carries the potential for adverse reactions typical of this drug class, primarily involving the gastrointestinal, hepatic, and renal systems.

Documented Adverse Reactions

System-Organ Class Common/Frequent Observations Serious/Clinically Significant Reactions
Gastrointestinal Vomiting, diarrhea, inappetence, soft stool, constipation Gastrointestinal ulceration, bleeding (melena, hematemesis), perforation
Hepatic (Liver) Elevated liver enzymes (ALT, AST, SAP) Acute hepatic toxicity/disorder, jaundice, hepatic failure (rare)
Renal (Kidney) Increased thirst (polydipsia), increased urination (polyuria), elevated renal parameters Acute renal failure, oliguria, hematuria
Systemic/Neurologic Lethargy, incoordination, behavior changes Seizures, ataxia, paresis, paralysis, severe allergic/hypersensitivity reactions

Serious adverse reactions may occur in rare situations, sometimes without pre-warning, and have been associated with fatality.

Safety Restrictions and Contraindications

This medication is contraindicated in individuals with known hypersensitivity to carprofen or other NSAIDs. It should not be used in patients with severe cardiac, hepatic, or renal disease, or where there is evidence of gastrointestinal ulceration or bleeding.

Caution is required in dehydrated, hypovolemic, or hypotensive patients, as these conditions increase the risk of renal toxicity. Concurrent use with other NSAIDs or corticosteroids is explicitly avoided due to the significant risk of increased adverse reactions, including severe gastrointestinal complications. Safety has not been established for use in young animals (under 6 weeks of age), pregnant animals, or those used for breeding.

High-Level Safety Monitoring

Regulatory documentation emphasizes that clinical effects are generally reversible upon cessation of administration. Patients at high risk for toxicity are those with pre-existing conditions (e.g., cardiac, renal, or hepatic dysfunction). Monitoring of liver and kidney function is often recommended prior to and periodically during long-term therapy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents specify that Carprotab overdosage is associated with a range of acute clinical manifestations. These signs primarily involve the gastrointestinal system (vomiting, diarrhea, melena, ulceration), systemic changes (lethargy, increased water/urine output), neurological effects (ataxia, seizure), and indications of hepatic compromise (jaundice, enzyme elevation).


Feature Official Regulatory Statement
Severe Outcomes Overdose may result in life-threatening conditions, including Acute Renal Failure, Acute Hepatic Toxicity, Gastrointestinal Perforation, and, in rare instances, Death.
Emergency Action Immediate veterinary assistance is required upon suspected ingestion above the labeled dose or the observation of adverse effects. Therapy must be stopped immediately.

Overdose Management and Risk Factors

No specific antidote is known for Carprofen overdosage. Management therefore relies on the application of general supportive therapy and symptomatic measures, including decontamination, gastrointestinal protection, and renal support, as described in official labeling. Furthermore, regulatory documents identify certain conditions that amplify risk: patients that are dehydrated or have pre-existing renal, hepatic, or cardiovascular dysfunction are noted as being at increased risk for acute toxicity in an overdose scenario. The severe potential for organ damage dictates that urgent attention must be sought immediately.

Therapeutic Uses of Carprotab

What Carprotab Treats: Main Uses and Benefits


The primary therapeutic function of Carprotab is to provide supportive symptomatic relief across key domains of pain, inflammation, and fever, and may assist with easing challenging symptoms associated with various clinical situations. The medication is explicitly used for easing pain and inflammation associated with musculoskeletal conditions and is relevant for easing discomfort following acute episodes.

Key Therapeutic Focus

Carprotab is applied across domains where additional symptomatic support is needed, primarily addressing conditions characterized by periods of heightened symptoms such as osteoarthritis and degenerative joint disease. It is also commonly used for short-term assistance during phases of increased distress or discomfort following soft tissue or orthopedic surgeries. The medication helps address symptom clusters that may intensify over time, including persistent stiffness, lameness, localized swelling, and fever. This supportive approach provides support that helps ease the overall symptom burden and may contribute to maintaining functional stability.


Quick Fact: Supportive Relief for Symptoms of Joint Discomfort
Primary Indication Focus Supportive management of chronic osteoarthritis symptoms.
Acute Scenario Supportive relief in scenarios following surgical procedures.
Symptom Reduction Addresses symptoms related to inflammatory or irritative states, pain, and fever.

Regulatory References

  1. U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine

Eligibility and Restrictions for Use

Carprotab, containing the active ingredient Carprofen, is regulated by global health authorities strictly as a Veterinary Medicinal Product and is not for human use. Its official eligibility profile is defined by specific exclusions and conditional use guidelines for its authorized target species (dogs).

Contraindicated Populations

Official labeling mandates that the product must not be used in:

  • Humans (Not for human consumption or use).
  • Cats (Explicitly contraindicated).
  • Dogs with known hypersensitivity to carprofen or other non-steroidal anti-inflammatory drugs (NSAIDs).
  • Dogs suffering from cardiac, hepatic, or renal disease or those with a possibility of gastro-intestinal ulceration, bleeding, or blood dyscrasia.

Restricted and Unestablished Use

Use is restricted or requires special consideration and monitoring in:

  • Aged or Senior Dogs (May require reduced dosage and careful clinical management).
  • Dogs who are dehydrated or on concomitant diuretic therapy, due to risk of increased renal toxicity.

The safe use has not been established in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches.

What should I know about interactions with other medicines?

Interaction Profile: Regulatory Documentation

The official regulatory profile for Carprotab is defined by documented interactions with several key medicinal product categories, established through government prescribing information.

Interaction Scope

Interactions are formally documented with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Glucocorticoids/Corticosteroids, Anticoagulants, Potentially Nephrotoxic Drugs, and other Highly Protein-Bound Drugs. The mechanistic basis involves both Pharmacodynamic (PD) reinforcement of adverse effects and Pharmacokinetic (PK) displacement due to high plasma protein binding.

Interaction Classifications

Interactions are classified as Contraindicated Combinations (NSAIDs, Glucocorticoids) or Combinations to be Avoided (Anticoagulants, Nephrotoxic Drugs). Increased risk of renal toxicity is noted for patients that are dehydrated, hypovolaemic, or hypotensive.

Official Interaction Statements

  • A strict prohibition exists for co-administering Carprotab with Glucocorticoids/Corticosteroids or other NSAIDs.
  • A mandatory time restriction requires a 24-hour separation when switching administration to or from another NSAID.
  • Co-administration with other highly protein-bound drugs may increase the plasma concentration and potential toxicity of the co-administered medicine due to PK displacement.
  • The concurrent use of Anticoagulants and Potentially Nephrotoxic Drugs should be avoided due to the increased risk of bleeding and renal toxicity, respectively.

This structure reflects the constraints defined by regulatory authorities to manage risks associated with additive toxicity and altered drug exposure.

Mechanism of Action

Targeted Inhibition of Inflammatory Prostaglandin Synthesis

Carprotab’s primary action involves the preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme, which is responsible for synthesizing pro-inflammatory prostaglandins from arachidonic acid . By blocking this molecular step, the drug initiates a cascade that directly reduces the production of these key chemical mediators, leading to a functional consequence of reduction of pro-inflammatory eicosanoid levels at the site of tissue irritation.


Modulating Nociceptor Signaling and Central Thermoregulation

The molecular inhibition of prostaglandin synthesis leads to two distinct physiological consequences. Peripherally, the reduction in chemical mediators decreases the sensitization of nociceptors (pain-sensing nerves), thus modulating afferent nociceptor signaling. Centrally, the same inhibitory mechanism acts on the hypothalamus to reset the body's elevated temperature set-point, influencing the hypothalamic thermal set-point.

Dosage and Administration Information

Carprotab (carprofen) is a non-steroidal anti-inflammatory drug (NSAID) prescribed by licensed veterinarians for the relief of pain and inflammation in dogs, such as that associated with osteoarthritis or post-operative pain. This medication is for use in dogs only and is not approved for use in cats.

Administration Guidelines

Carprotab tablets are administered orally. The dose and duration of treatment are determined by your veterinarian based on your dog's weight, condition, and response to therapy. Follow the veterinarian's instructions exactly regarding the amount and frequency of dosing, and do not change the dosage without consultation.

  • Dosing: Carprofen is typically administered once a day or is divided into two equal doses given every 12 hours. The recommended dose is generally 4.4 mg per kilogram (2.0 mg per pound) of body weight daily.
  • With or Without Food: The tablet may be given with or without food. However, administration with a small amount of food may help reduce the chance of gastrointestinal upset.
  • Missed Dose: If a dose is missed, administer it as soon as you remember, unless it is close to the time for the next scheduled dose. If so, skip the missed dose and resume the regular schedule. Do not give two doses at once or give extra doses.

Important Monitoring and Precautions

Before initiating treatment, a thorough physical examination and appropriate laboratory tests to establish baseline blood values are strongly recommended and should be performed periodically during long-term therapy. Stop administration and contact your veterinarian immediately if you observe any signs of potential adverse effects, such as vomiting, diarrhea, changes in appetite, or lethargy.

Do not administer Carprotab concurrently with other NSAIDs or corticosteroids due to an increased risk of serious adverse reactions, including gastrointestinal complications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Carprotab


Evidence for Chronic Osteoarthritis (OA) in Dogs

Research exploring the compound Carprotab was studied for its relevance in contexts of conditions characterized by fluctuating symptoms associated with chronic osteoarthritis. This foundation of evidence is largely based on controlled clinical studies, including Randomized Controlled Trials (RCTs) and multicenter field trials, that have included adult dogs diagnosed with naturally occurring OA. Researchers primarily focused on outcomes related to daily functioning and activity level, such as changes in how the animal uses its limbs and overall lameness grade.

Studies reported patterns of change in measured weight-bearing function and lameness grades when compared against placebo in specific trial settings. Findings also described how subjective assessments of the animal's overall status evolved during the study period. While the available evidence for this indication is significant, long-term effects are not fully established regarding any potential impact on the underlying joint structure over the animal’s lifetime.


Evidence for Acute Symptom Management Following Surgery

The evidence for the use of Carprotab in the post-operative setting involves acute, short-term, controlled clinical field trials. Research examined the compound's application in studies conducted during periods of increased symptom activity, specifically after soft tissue or orthopedic surgeries. The primary outcomes monitored were outcomes related to physical discomfort and the need for rescue analgesia during the immediate recovery period.

Trials described patterns of change in the measured pain scores and evolution of signs related to acute post-surgical swelling across the short observation period. The focus of this evidence base is on immediate, acute symptom control, meaning that follow-up durations were limited, typically covering only the initial 1 to 3 days after the procedure. Therefore, there is limited information for extended functional recovery beyond the immediate surgical period.


Evidence Gaps and Research Uncertainty

Research highlights what is known — and what is still uncertain — about Carprotab. One key area is the lack of research specifically examining long-term structural changes within the joint itself, meaning that existing studies provide limited insight into whether the compound affects the progression of the underlying condition. Furthermore, evidence quality varies across studies, particularly when results are compared with newer therapeutic options, and comparative evidence is lacking for certain alternative treatments.

Key Studies & References

  1. FDA Freedom of Information Summary: RIMADYL (Carprofen) Chewable Tablets

Frequently Asked Questions (FAQ)

Common questions about Carprotab (FAQ)


Q: How long does it take for Carprotab to start working?

Official studies indicate that the active ingredient in Carprotab reaches its highest concentration in the dog's bloodstream approximately 1 to 3 hours after the tablet is given by mouth. This time frame indicates when the concentration of the medication is highest in the blood.


Q: Can I give Carprotab to my puppy?

According to the official product information, the safe use of this medication has not been established in animals that are younger than 6 weeks of age. For dogs falling into this age group, a consultation with a veterinarian is required to weigh the potential benefits against any risks, based on the dog's specific condition.


Q: What are the signs of a serious overdose or toxicity in my dog?

Signs of toxicity, as noted in the regulatory documentation, can affect several body systems. These signs may include gastrointestinal issues, such as bloody vomit or black, tarry stool. They can also involve changes in kidney function, such as noticeably increased thirst or urination, or serious neurological signs, such as seizures. If these signs are observed, contact a veterinarian immediately for guidance.


Q: What are the contraindications for a dog with a bleeding disorder?

Official documentation indicates that the safe use of Carprotab has not been established in dogs with diagnosed bleeding disorders, such as Von Willebrand’s disease. It is important to discuss any underlying bleeding conditions with a veterinarian before treatment begins.


Q: How long can my dog stay on Carprotab safely?

The duration of Carprotab administration is determined by a veterinarian, based on the specific condition being treated and the dog’s response. For chronic issues like osteoarthritis, long-term administration may be needed, which requires laboratory tests to be performed periodically for monitoring, as recommended in the official product labeling.


Q: Is there a human version of this medication?

The active ingredient, carprofen, is an NSAID that was previously utilized in human medicine for a period of time. However, it is currently authorized and regulated only as a veterinary medicinal product and is strictly not intended for human consumption.


Q: What should I do if my dog is vomiting after taking the tablet?

If your dog vomits after taking the tablet, official guidelines suggest that for the next dose, you may try giving the tablet with food or a small treat to help reduce the chance of stomach upset. If vomiting continues or if signs of intolerance are noted, it is important to stop giving the medication and contact a veterinarian for guidance.

How should Carprotab be stored and disposed of?

How to Store and Dispose of Carprotab

The medicine must be stored at controlled room temperature, maintaining a required range between 15 C and 30 C (59 F and 86 F). The container must be kept tightly closed and protected from light. For specific scored tablets, any half-tablet must be used within 30 days.

Safety and Handling

Carprotab must be kept out of the reach of children and stored in a secured area out of the reach of dogs due to potential toxicity from accidental ingestion. The product should be stored away from incompatible chemicals such as strong acids or oxidizers.

Disposal

Disposal of unused or expired medicine must comply with local, regional, and national regulations. To protect the environment, the product must not be discharged into drains, water courses, or onto the ground. If no take-back program is available, unused tablets should be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carprotab found in:

A-Z Index: